A patient with angina at night: core curriculum chapters 3 (non-invasive imaging) and 9 (chronic ischaemic heart disease)
暂无分享,去创建一个
F. Eberli | A. Wieczorek | A. Kastrati | J. Mehilli | S. Windecker | J. Pache | J. Hausleiter | A. Schömig | M. Morice | W. Wijns | P. Buszman | K. Laugwitz | R. Byrne | C. Mario | A. Linke | S. Massberg | P. Eerdmans | S. Schulz | M. Fusaro | A. Dibra | Mehilli J. Biodegradable | Kastrati A. Everolimus-eluting
[1] F. Eberli,et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.
[2] M. Hadamitzky,et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. , 2011, Journal of the American College of Cardiology.
[3] F. Eberli,et al. Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.